Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QK1R | ISIN: KYG4987A1094 | Ticker-Symbol: 77V
Frankfurt
21.11.24
09:59 Uhr
0,189 Euro
-0,001
-0,53 %
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
JACOBIO PHARMACEUTICALS GROUP CO LTD Chart 1 Jahr
5-Tage-Chart
JACOBIO PHARMACEUTICALS GROUP CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,1850,20615:19

Aktuelle News zur JACOBIO PHARMACEUTICALS GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.10.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT GLECIRASIB FOR THE TREATMENT OF PANCREATIC CANCER HAS BEEN GRANTED ORPHAN DRUG DESIGNATION IN EUROPE1
18.10.JACOBIO-B (01167): NEXT DAY DISCLOSURE RETURN-
09.10.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO PRESENTED THE PRE-CLINICAL DATA OF SHP2 INHIBITOR JAB-3312 IN COMBINATION WITH KRAS G12C INHIBITOR GLECIRASIB ...-
08.10.JACOBIO-B (01167): NEXT DAY DISCLOSURE RETURN-
03.10.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO TO PRESENT THE CLINICAL DATA OF BET INHIBITOR JAB-8263 AT THE 2024 66TH AMERICAN SOCIETY OF HEMATOLOGY ...1
27.09.JACOBIO-B (01167): 2024 INTERIM REPORT-
27.09.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED UPFRONT PAYMENT UPON THE ENTRY INTO EXCLUSIVE LICENSING-OUT AGREEMENT FOR GLECIRASIB AND JAB- ...1
JACOBIO PHARMACEUTICALS GROUP Aktie jetzt für 0€ handeln
26.09.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED CHINA CDE INVESTIGATIONAL NEW DRUG CLEARANCE FOR PAN-KRAS INHIBITOR JAB-23E731
23.09.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED INVESTIGATIONAL NEW DRUG (IND) APPROVAL FROM THE U.S. FDA FOR PAN-KRAS INHIBITOR JAB-23E731
04.09.Allist pays Jacobio $21M for KRAS drug combo, landing leading role in Chinese cancer race1
02.09.Jacobio Pharma grants Allist rights to two assets in China1
30.08.JACOBIO-B (01167): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS1
30.08.JACOBIO-B (01167): (1) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024; (2) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (3) CHANGE ...1
30.08.JACOBIO-B (01167): INSIDE INFORMATION - JACOBIO ANNOUNCES EXCLUSIVE LICENSING-OUT AGREEMENT WITH ALLIST FOR GLECIRASIB AND JAB-33121
21.08.JACOBIO-B (01167): SUPPLEMENTAL ANNOUNCEMENT TO THE 2023 INTERIM REPORT AND THE 2023 ANNUAL REPORT-
20.08.JACOBIO-B (01167): DATE OF BOARD MEETING1
07.08.JACOBIO-B (01167): VOLUNTARY ANNOUNCEMENT JACOBIO COMPLETED FIRST PATIENT DOSAGE IN THE PHASE III CLINICAL TRIAL OF JAB-3312 IN COMBINATION WITH GLECIRASIB1
25.06.XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 25.06.2024494The following instruments on XETRA do have their first trading 25.06.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.06.2024 Aktien 1 US76657Y1010 Rightmove PLC ADR 2...
► Artikel lesen
21.06.JACOBIO-B (01167): NEXT DAY DISCLOSURE RETURN1
13.06.JACOBIO-B (01167): NEXT DAY DISCLOSURE RETURN1
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1